AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
quinidine ๐ถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2346 | 56-54-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 11.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 18 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 30.82 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.90 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.26 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 6.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.018 | Moderate | 0.74 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.436 | Moderate | 0.74 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 18.408 | 10^-6 cm/s | Moderate | 0.74 |
| dh-clint | Dog hepatocyte intrinsic clearance | 8.204 | uL/min/10^6 cells | Moderate | 0.74 |
| dppb | Dog plasma protein binding (% unbound) | 22.830 | % | Moderate | 0.74 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 46.380 | % | Moderate | 0.74 |
| herg | hERG pIC50 | 5.636 | pIC50 | Moderate | 0.74 |
| hh-clint | Human hepatocyte intrinsic clearance | 4.198 | uL/min/10^6 cells | Moderate | 0.74 |
| hlm-clint | Human liver microsomal intrinsic clearance | 32.961 | uL/min/mg protein | Moderate | 0.74 |
| hppb | Human plasma protein binding (% unbound) | 23.480 | % | Moderate | 0.74 |
| kinase-safety-class | ACVR2B,AXL,CAMK2D,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4,PRKDC | 10 | |||
| kinase-selectivity-class | AXL,CAMK2D,CDK9,EIF2AK3,MAP2K6 | 5 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 12.331 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 6.934 | Moderate | 0.74 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 75.336 | Moderate | 0.74 | |
| mppb | Mouse plasma protein binding (% unbound) | 22.340 | Moderate | 0.74 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 31.189 | Moderate | 0.74 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 | |
| pppb | Pig plasma protein binding (% unbound) | 38.630 | % | Moderate | 0.74 |
| rat-kpuu-brain | Rat brain Kpuu | 0.031 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 60.395 | uL/min/10^6 cells | Moderate | 0.74 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 66.510 | % | Moderate | 0.74 |
| rppb | Rat plasma protein binding (% unbound) | 29.280 | % | Moderate | 0.74 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 849.180 | uM | Moderate | 0.74 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 12, 1950 | FDA | LILLY |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gliosis | 98.55 | 50.44 | 14 | 820 | 481 | 90627132 |
| Polyserositis | 94.25 | 50.44 | 14 | 820 | 659 | 90626954 |
| Pouchitis | 94.17 | 50.44 | 14 | 820 | 663 | 90626950 |
| Premature menopause | 84.73 | 50.44 | 14 | 820 | 1315 | 90626298 |
| Ovarian failure | 81.77 | 50.44 | 14 | 820 | 1629 | 90625984 |
| Somatic symptom disorder | 77.58 | 50.44 | 15 | 819 | 3426 | 90624187 |
| Antiphospholipid syndrome | 77.22 | 50.44 | 14 | 820 | 2260 | 90625353 |
| Venous thrombosis limb | 71.35 | 50.44 | 14 | 820 | 3448 | 90624165 |
| Cardiac tamponade | 64.55 | 50.44 | 14 | 820 | 5618 | 90621995 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 117.26 | 40.81 | 67 | 275 | 630130 | 41990863 |
| Electrocardiogram QT prolonged | 44.39 | 40.81 | 16 | 326 | 47929 | 42573064 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gliosis | 90.50 | 38.25 | 14 | 1206 | 718 | 110587361 |
| Ovarian failure | 86.48 | 38.25 | 14 | 1206 | 962 | 110587117 |
| Polyserositis | 85.67 | 38.25 | 14 | 1206 | 1020 | 110587059 |
| Premature menopause | 85.56 | 38.25 | 14 | 1206 | 1028 | 110587051 |
| Pouchitis | 81.46 | 38.25 | 14 | 1206 | 1383 | 110586696 |
| Somatic symptom disorder | 76.10 | 38.25 | 15 | 1205 | 3144 | 110584935 |
| Antiphospholipid syndrome | 73.20 | 38.25 | 14 | 1206 | 2509 | 110585570 |
| Electrocardiogram QT prolonged | 68.06 | 38.25 | 30 | 1190 | 108930 | 110479149 |
| Drug ineffective | 65.06 | 38.25 | 81 | 1139 | 1520459 | 109067620 |
| Venous thrombosis limb | 62.93 | 38.25 | 14 | 1206 | 5251 | 110582828 |
| Cardiac tamponade | 52.29 | 38.25 | 14 | 1206 | 11293 | 110576786 |
| Proctectomy | 45.58 | 38.25 | 7 | 1213 | 341 | 110587738 |
| Lupus-like syndrome | 41.69 | 38.25 | 16 | 1204 | 40776 | 110547303 |
| Intervertebral disc protrusion | 39.93 | 38.25 | 14 | 1206 | 27684 | 110560395 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BA01 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ia |
| ATC | C01BA51 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ia |
| ATC | C01BA71 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ia |
| FDA EPC | N0000175426 | Antiarrhythmic |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000962 | Antimalarials |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D000317 | Adrenergic alpha-Antagonists |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
| MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
| MeSH PA | D065690 | Cytochrome P-450 CYP2D6 Inhibitors |
| FDA EPC | N0000182135 | Cytochrome P450 2D6 Inhibitor |
| FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
| CHEBI has role | CHEBI:176497 | geroprotector |
| CHEBI has role | CHEBI:37890 | ฮฑ-adrenergic antagonist |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:38633 | sodium channel blocker |
| CHEBI has role | CHEBI:48876 | muscarinic antagonist |
| CHEBI has role | CHEBI:50183 | P450 inhibitor |
| CHEBI has role | CHEBI:50509 | potassium channel blocker |
| CHEBI has role | CHEBI:77748 | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor |
| CHEBI has role | CHEBI:77781 | EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor |
| CHEBI has role | CHEBI:88188 | drug allergen |
Related Drugs by ATC class:
C01BA Antiarrhythmics, class Ia 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Atrial fibrillation | indication | 49436004 | DOID:0060224 |
| Malaria | indication | 61462000 | DOID:12365 |
| Pseudobulbar affect | indication | 432776007 | |
| Life-Threatening Ventricular Tachycardia | indication | ||
| Cardioversion of Atrial Fibrillation | indication | ||
| Psoriasis | contraindication | 9014002 | DOID:8893 |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Left ventricular hypertrophy | contraindication | 55827005 | |
| Poisoning by quinidine | contraindication | 59826007 | |
| Left bundle branch block | contraindication | 63467002 | |
| Left heart failure | contraindication | 85232009 | |
| Pulmonary emphysema | contraindication | 87433001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Partial atrioventricular block | contraindication | 195039008 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Non-specific intraventricular conduction delay | contraindication | 698252002 | |
| Digitalis Toxicity with AV Conduction Defects | contraindication |
๐ถ Veterinary Drug Use
None
๐ถ Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.44 | acidic |
| pKa2 | 8.02 | Basic |
| pKa3 | 4.1 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 20MG;10MG | NUEDEXTA | OTSUKA AMERICA PHARM | N021879 | Oct. 29, 2010 | RX | CAPSULE | ORAL | 7659282 | Aug. 13, 2026 | TREATMENT OF PSEUDOBULBAR AFFECT |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | BLOCKER | IC50 | 5.49 | CHEMBL | CHEMBL | |||
| Sodium channel protein type 5 subunit alpha | Ion channel | BLOCKER | IC50 | 5.16 | CHEMBL | CHEMBL | |||
| Cytochrome P450 2D6 | Enzyme | INHIBITOR | Ki | 7.92 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Sodium channel subunit beta-3 | Ion channel | WOMBAT-PK | |||||||
| Sodium channel subunit beta-4 | Ion channel | WOMBAT-PK | |||||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.49 | CHEMBL | |||||
| Multidrug resistance protein 1 | Transporter | Ki | 5.59 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.13 | PDSP | |||||
| Cholinesterase | Enzyme | IC50 | 5.91 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily A member 5 | Ion channel | BLOCKER | Kd | 5.20 | IUPHAR | ||||
| Potassium channel subfamily T member 1 | Ion channel | IC50 | 4.80 | CHEMBL | |||||
| Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | IC50 | 4.11 | WOMBAT-PK | |||||
| Potassium voltage-gated channel subfamily A member 7 | Ion channel | BLOCKER | Kd | 4.80 | IUPHAR | ||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 4.06 | WOMBAT-PK | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 4.95 | CHEMBL | |||||
| Equilibrative nucleoside transporter 4 | Transporter | INHIBITOR | Ki | 4.60 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily H member 1 | Ion channel | BLOCKER | IC50 | 5.80 | IUPHAR | ||||
| Sodium channel subunit beta-1 | Ion channel | WOMBAT-PK | |||||||
| Sodium channel subunit beta-2 | Ion channel | WOMBAT-PK | |||||||
| Sodium channel protein type 5 subunit alpha | Ion channel | BLOCKER | IC50 | 5 | IUPHAR | ||||
| Cholinesterase | Enzyme | IC50 | 5.13 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily D member 2 | Ion channel | IC50 | 5.66 | CHEMBL | |||||
| Potassium channel subfamily T member 1 | Ion channel | BLOCKER | IC50 | 4 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4017419 | VUID |
| N0000179295 | NUI |
| D00642 | KEGG_DRUG |
| 27555-34-6 | SECONDARY_CAS_RN |
| 6591-63-5 | SECONDARY_CAS_RN |
| 7054-25-3 | SECONDARY_CAS_RN |
| 4017417 | VANDF |
| 4017418 | VANDF |
| 4017419 | VANDF |
| 4019925 | VANDF |
| C0034414 | UMLSCUI |
| CHEBI:28593 | CHEBI |
| QDN | PDB_CHEM_ID |
| CHEMBL1294 | ChEMBL_ID |
| CHEMBL1201486 | ChEMBL_ID |
| CHEMBL3707183 | ChEMBL_ID |
| DB00908 | DRUGBANK_ID |
| CHEMBL1200437 | ChEMBL_ID |
| D011802 | MESH_DESCRIPTOR_UI |
| 441074 | PUBCHEM_CID |
| 2342 | IUPHAR_LIGAND_ID |
| C047144 | MESH_SUPPLEMENTAL_RECORD_UI |
| C016713 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6151-40-2 | SECONDARY_CAS_RN |
| 1668-99-1 | SECONDARY_CAS_RN |
| ITX08688JL | UNII |
| 35220 | RXNORM |
| 2389 | MMSL |
| 2395 | MMSL |
| 5402 | MMSL |
| 5403 | MMSL |
| 5404 | MMSL |
| 72295 | MMSL |
| d00020 | MMSL |
| 000618 | NDDF |
| 000619 | NDDF |
| 000620 | NDDF |
| 000621 | NDDF |
| 004377 | NDDF |
| 1217203007 | SNOMEDCT_US |
| 31306009 | SNOMEDCT_US |
| 372697008 | SNOMEDCT_US |
| 5907009 | SNOMEDCT_US |
| 77632008 | SNOMEDCT_US |
| 82230005 | SNOMEDCT_US |
| CHEMBL2165709 | ChEMBL_ID |
| ITX08688JL | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dextromethorphan hydrobromide and quinidine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 31722-693 | CAPSULE | 10 mg | ORAL | ANDA | 28 sections |
| QUINIDINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-512 | TABLET | 300 mg | ORAL | ANDA | 20 sections |
| QUINIDINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-513 | TABLET | 200 mg | ORAL | ANDA | 20 sections |
| Quinidine Gluconate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-288 | TABLET, EXTENDED RELEASE | 324 mg | ORAL | ANDA | 26 sections |
| Quinidine Gluconate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53489-141 | TABLET, EXTENDED RELEASE | 324 mg | ORAL | ANDA | 26 sections |
| Nuedexta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 59148-053 | CAPSULE, GELATIN COATED | 10 mg | ORAL | NDA | 27 sections |
| NUEDEXTA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64597-301 | CAPSULE, GELATIN COATED | 10 mg | ORAL | NDA | 27 sections |
| NUEDEXTA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64597-301 | CAPSULE, GELATIN COATED | 10 mg | ORAL | NDA | 27 sections |
| Quinidine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1991 | TABLET | 200 mg | ORAL | ANDA | 13 sections |
| Quinidine Gluconate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2701 | TABLET, EXTENDED RELEASE | 324 mg | ORAL | ANDA | 25 sections |
| Quinidine gluconate | Human Prescription Drug Label | 1 | 71930-016 | TABLET, EXTENDED RELEASE | 324 mg | ORAL | ANDA | 13 sections |